New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

NDT Plus

Volumn 1, Issue SUPPL.3, 2008, Pages

  Onoda, Noritaka ^a   Fukagawa, Masafumi ^b   Tominaga, Yoshihiro ^b   Kitaoka, Masafumi ^b   Akizawa, Tadao ^b   Koiwa, Fumihiko ^b   Kakuta, Takatoshi ^b   Kurokawa, Kiyoshi ^b  

^a Sekishinkai Sayama Hospital   (Japan)

^b NONE

Author keywords

Nodular hyperplasia; Percutaneous ethanol injection therapy (PEIT); Percutaneous vitamin D injection therapy (PDIT); Secondary hyperparathyroidism; Ultrasonography

Indexed keywords

22 OXACALCITRIOL; ALCOHOL; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D DERIVATIVE;

CALCIUM BLOOD LEVEL; CLINICAL PROTOCOL; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; INFORMED CONSENT; MEDICAL SOCIETY; NODULAR HYPERPLASIA; PARATHYROID FUNCTION; PARATHYROID GLAND; PERCUTANEOUS ETHANOL INJECTION THERAPY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY; THERAPY;

EID: 48749092956     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn083     Document Type: Short Survey

References (24)

1. Solbiati L, Giangrande A, Pra LD et al. Percutaneous ethanol injection of parathyroid tumors under US guidance: treatment for secondary hyperparathyroidism. Radiology 1985; 155: 607-610
2. Karstrup S, Holm HH, Torp-Pedersen S et al. Ultrasonically guided percutaneous inactivation of parathyroid tumours. Br J Radiol 1987; 60: 667-670
3. Takeda S, Michigishi T, Takazakura E et al. Successful ultrasonically guided percutaneous ethanol injection for secondary hyperparathyroidism. Nephron 1992; 62: 100-103
4. Tominaga Y, Sato K, Tanaka M et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 78-86
5. 3 receptor density is associated with amore severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
6. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
7. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48: 259-272
8. Fukagawa M. Cell biology of parathyroid hyperplasia in uremia. Am J Med Sci 1999; 317: 377-382
9. Kitaoka M, Fukagawa M, Ogata E et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-1117
10. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999; 33: 1091-1099
11. Nakamura M, Fuchinoue S, Teraoka S. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism. Am J Kidney Dis 2003; 739-745
12. Tanaka M, Itoh K, Matsushita K et al. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines. Ther Apher Dial 2005; 9: 48-52
13. Fukagawa M, Kitaoka M, Tominaga Y et al. Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients-the Japanese strategy. Nephrol Dial Transplant 1999; 14: 2574-2577
14. Tanaka M, Itoh K, Matsushita K et al. Combination therapy of intravenous Maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract 2006; 102: c1-c7
15. Fukagawa M, Kitaoka M, Tominaga Y et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 2003; 18(Suppl 3): iii31-iii33
16. Tominaga Y, Kitaoka M, Fukagawa M et al. Guideline of selective parathyroid percutaneous ethanol injection therapy for patients with advanced renal hyperparathyroidism. J Jpn Soc Dial Ther 1999; 32: 1099-1103 (in Japanese)
17. The Japanese Society for Dialysis Therapy. Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients. J Jpn Soc Dial Ther 2006; 39: 1435-1455 (in Japanese)
18. Kitaoka M, Onoda N, Kitamura H et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003; 18(Suppl 3): iii38-iii41
19. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003; 64: 992-1003
20. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism ?. Ther Apher Dial 2006; 10: 198-204
21. Koiwa F, Kakuta T, Tanaka R et al. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2006; 22: 522-528
22. Onoda N, Kashiwagi T, Nakamura T et al. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients. Ther Apher Dial 2005; 9(Suppl 1): s11-s15
23. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003; 64: 992-1003
24. Shiizaki K, Negi S, Hatamura I et al. Biochemical and cellular effects of direct Maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 2005; 16: 97-108